Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large increase in short interest in July. As of July 15th, there was short interest totaling 574,897 shares, an increase of 98.3% from the June 30th total of 289,957 shares. Based on an average daily volume of 30,260,865 shares, the short-interest ratio is currently 0.0 days. Approximately 16.9% of the company’s stock are short sold.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the Securities & Exchange Commission. 20.34% of the stock is currently owned by institutional investors.

Catheter Precision Stock Down 1.8%

Shares of Catheter Precision stock traded down $0.01 on Thursday, hitting $0.28. 645,570 shares of the company’s stock traded hands, compared to its average volume of 18,434,328. Catheter Precision has a 52-week low of $0.23 and a 52-week high of $4.31. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. The stock has a market cap of $1.00 million, a P/E ratio of -0.02 and a beta of -1.07. The firm’s 50-day moving average is $0.81 and its 200 day moving average is $1.18.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.